pp-227 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Sickle Cell Disease & Lower-Risk Myelodysplastic Syndromes (LR-MDS) / Clinical stage: Phase 2 / Modality: Small molecule pyruvate kinase activator / Mechanism & Target: PK activator, next-gen formulation / Route & form: Oral / Differentiation: Improved profile vs mitapivat
Manufacturer #39434
Clinical-stage biopharmaceutical company specializing in central nervous system disorders. Develops novel small molecules targeting psychiatric, neurological, and rare CNS conditions. Pursues multiple Phase 2 and Phase 3 programs through global development initiatives.
None